Novel SLC12A2‐ROS1 Fusion in Non‐Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next‐Generation Sequencing Assay

Identifying the druggable target is crucial for patients with nonsquamous advanced non‐small cell lung cancer (NSCLC). This article adds to the spectrum of ROS1 fusion cases described in NSCLC. We describe a novel SLC12A2‐ROS1 rearrangement that has not been previously reported in other cancers: a f...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodríguez‐Antolín, Carlos, Rosas‐Alonso, Rocío, Cruz, Patricia, Higuera, Oliver, Sánchez‐Cabrero, Darío, Esteban‐Rodríguez, Isabel, Peláez‐García, Alberto, Fernández Montaño, Victoria Eugenia, Rodríguez‐Jiménez, Carmen, Ibáñez de Cáceres, Inmaculada, de Castro, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Precision Medicine Clinic: Molecular Tumor Board
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176992/
https://www.ncbi.nlm.nih.gov/pubmed/33682977
http://dx.doi.org/10.1002/onco.13745

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176992/
https://www.ncbi.nlm.nih.gov/pubmed/33682977
http://dx.doi.org/10.1002/onco.13745

Ejemplares similares